Markets
Novo Nordisk Eyes China Wegovy Pill Approval: What Traders Need to Know
Novo Nordisk's CEO confirmed the company plans to seek regulatory approval for an oral Wegovy formulation in China imminently, opening a potential market of hundreds of millions of obese patients. The move could dramatically reshape the GLP-1 competitive landscape in the world's most populous nation.